45 results about "HIV Proteins" patented technology

A sample collection system capable of collecting, storing and dispensing a liquid sample is disclosed. The collection system includes a collector composed of a material which has the unique ability to express constituents of interest at levels which are much more concentrated than their levels in the fluid samples from which they are expressed, where the expressed highly concentrated sample can then be used with modern rapid screening / testing protocols, such as solid phase assays, to test for the constituents of interest. Thus, it is now possible to obtain analytes of interest, such as the HIV protein antibodies, from saliva samples at concentrations that are detectable with systems and / or devices that are typically utilized only for blood serum or plasma testing. The collector is sized and shaped to fit within a recovery container, which, in turn, is sized and shaped to fit within a collection tube. The recovery container includes an aperture which does not permit passage of fluid under ambient conditions, but facilitates transfer thereof when subjected to pressure. An optional channel within the collection tube facilitates dispensing of the sample for further processing.

The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative, which is non-glycosylated when expressed in a mammalian target cell, operably linked to a heterologous promoter. Preferably the HIV envelope molecule, such as gp120 or gp140 or gp160, lacks a functional secretion signal. It may be fused to additional HIV proteins such as Nef, Gag, RT or Tat.

Nucleic acids are disclosed encoding fusion proteins comprising the amino acid sequence of at least four non-attenuated HIV proteins selected from the group consisting of Vif, Vpr, Vpu, Vpx, Rev, Tat, and Nef, wherein the fusion protein does not contain a specific cleavage sequence for a cellular protease. Also disclosed are vectors comprising the nucleic acids and methods of preparing the fusion protein by transfecting a host cell with the nucleic acids or with the vectors containing the nucleic acids, expressing the fusion proteins, and recovering the fusion proteins.

The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative fused to an additional HIV protein selected from a non-structural protein or capsid protein or fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is gp120 and preferred fusions include one or more of HIV Nef, Gag, RT or Tat. Preferably the HIV envelope molecule is non-glycosylated in mammalian cells.

The present invention relates to a recombinant Modified Vaccinia virus Ankara (MVA) comprising in the viral genome one or more expression cassettes for the expression of HIV proteins selected from Gag, Pol, Tat, Vif, Vpu, Vpr, Rev and Nef or a part or a derivative thereof or selected from Gag, Pol, Vpu, Vpr, Rev and Nef or a part or a derivative thereof for use as medicament or vaccine and its use for the treatment and / or prevention of HIV infections and AIDS.

Disclosed is an immunogen in sterile form suitable for administration to a human subject, the immunogen comprising: at least a portion of the gag protein of HIV, said gag protein being from an HIV clade or having a consensus sequence for one or more HIV clades, and comprising at least parts of p17 and p24; and a synthetic polypeptide comprising a plurality of amino acid sequences, each sequence comprising a human CTL epitope of an HIV protein, and wherein a plurality of HIV proteins are represented in the synthetic polypeptide, said CTL epitopes being selected to stimulate an immune response to one or more HIV clades of interest.

The present invention provides a new semi-stable packaging cell line and a method to produce lentiviral vectors (LV), using the semi-stable packaging cell line. New methods and packaging cell lines of the invention are generated using a baculo-AAV hybrid system for stable expression of structural and regulatory lentiviral proteins, such system comprising a baculoviral backbone containing an integration cassette flanked by AAV ITRs, in combination with a plasmid encoding rep protein. This system allows to obtain a stable integration of the structural and regulatory HIV-1 proteins gag / pol and rev. The system allows to obtain a cell line including the structural and regulatory HIV proteins gag / pol and rev, to be used for a semi-stable LV production.

This invention is called: the experiment and method of the protein envelope which is allosteric restructuring of the HIV-Env gene DNA and its antigenic immunity responsive HIV. It relates to the domain of life sciences and medicine sciences. It is confirmed that gp120 of the HIV protein envelope or the gp160 of the antigenic vaccine combines with cell CD4+ that can induce the infirm immunogen of the alloantigen of the immune tolerant receptor CD4 and can not induce the HIV to infect the immune response of the parasitifer. It can also eliminate the multi-clone group of hill of the wild virus which is of fast copy the initial infection virus, high variability and sequence diversity. This invention can develop the non-spark human tolerant immunity HIV vaccine of the protein envelope which is allosteric restructuring of the HIV-Env gene DNA, the HIV preventive vaccine that can provide the scientific basis of the direct animal experiment and direct clinical trial of human being. It also provides the enforceable anti-HIV cell model, rodent model, non-human Primates model and the research program of human clinical trial.

Compositions and methods of use are provided to boost a primed immune response to HIV. More specifically, the present invention relates to vaccine compositions comprising an HIV-protein boost or an MVA-expressed Env protein and methods of use. Exemplary HIV proteins for protein boosts include proteins such as gp120 proteins B.63521Δ11mutC and full-length single chain (FLSC), which has been modified to stabilize a CD4-induced Env structure. Exemplary MVAs expressing secreted Methods of administration and dosing regimens are also provided.

A sample collection system capable of collecting, storing and dispensing a liquid sample is disclosed. The collection system includes a collector composed of a material which has the unique ability to express constituents of interest at levels which are more concentrated than their levels in the fluid samples from which they are expressed, where the expressed highly concentrated sample can then be used with modern rapid screening / testing protocols, such as solid phase assays, to test for the constituents of interest. Thus, it is now possible to obtain analytes of interest, such as the HIV protein antibodies, from saliva samples at concentrations that are representative of that found in serum or plasma. The collector is sized and shaped to fit within a recovery container, which, in turn, is sized and shaped to fit within a collection tube. The recovery container includes an aperture which does not permit passage of fluid under ambient conditions, but facilitates transfer thereof when subject to pressure. An optional channel within the collection tube facilitates dispensing of the sample for further processing.

The present invention relates to nucleic acid and attenuated vaccinia vectors for prophylactic use against HIV infection, as well as methods of eliciting immune responses in subjects susceptible to HIV infection. The prophylactic vaccine regimen of the invention involves immunological priming with an inoculum comprising two novel DNA vectors, followed by boosting with a Modified Vaccinia Ankara (MVA) recombinant viral vector expressing the corresponding HIV proteins.

A sample collection system capable of collecting, storing and dispensing a liquid sample is disclosed. The collection system includes a collector composed of a material which has the unique ability to express constituents of interest at levels which are much more concentrated than their levels in the fluid samples from which they are expressed, where the expressed highly concentrated sample can then be used with modern rapid screening / testing protocols, such as solid phase assays, to test for the constituents of interest. Thus, it is now possible to obtain analytes of interest, such as the HIV protein antibodies, from saliva samples at concentrations that are detectable with systems and / or devices that are typically utilized only for blood serum or plasma testing. The collector is sized and shaped to fit within a recovery container, which, in turn, is sized and shaped to fit within a collection tube. The recovery container includes an aperture which does not permit passage of fluid under ambient conditions, but facilitates transfer thereof when subjected to pressure. An optional channel within the collection tube facilitates dispensing of the sample for further processing.

Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.

An improved method of inducing protective immunity to the Human Immunodeficiency Virus through isolating a person's antigen-presenting cells from blood, then pulsing these cells with short peptides that bind the person's Class I Major Histocompatibility Complex Types and correspond to conserved segments of the HIV structural and functional genes. These pulsed dendritic cells are then injected intravenously, where they will travel to lymph tissue and prime HIV-specific Cytotoxic T Lymphocytes. The immune system is then activated by injecting the person with a weakened arbovirus, Chikungunya. The interferons and other immune-activating chemicals induced by the virus will stimulate creation of billions of killer cells that recognize HIV proteins, allowing for rapid mobilization of memory immune cells to contain and eliminate any subsequent infection with the HIV virus. The vaccine is custom-designed to each person and uses no HIV virus for safety purposes. It is understood that the examples an embodiments described herein are for illustrative purposes only and various changes or modifications in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

Compositions and methods of use are provided to boost a primed immune response to HIV. More specifically, the present invention relates to vaccine compositions comprising an HIV-protein boost or an MVA-expressed Env protein and methods of use. Exemplary HIV proteins for protein boosts include proteins such as gp120 proteins B.63521Δ11mutC and full-length single chain (FLSC), which has been modified to stabilize a CD4-induced Env structure. Exemplary MVAs expressing secreted Methods of administration and dosing regimens are also provided.

The present invention provides new stable packaging cell lines and producer cell lines as well as methods to obtain them, and a new method to produce lentiviral vectors using such cell lines. New methods and packaging cell lines of the invention are generated using a baculo-AAV hybrid system for stable expression of structural and regulatory lentiviral proteins, such system comprising a baculoviral backbone containing an integration cassette flanked by AAV ITR, in combination with a plasmid encoding rep protein. This system allows to obtain a stable integration of the structural and regulatory HIV-1 proteins gag / pol and rev. The system allows to obtain a first intermediate including only the structural and regulatory HIV proteins gag / pol and rev, to be used as starting point to obtain stable packaging cell lines as well as producer cell lines.